Brain endothelial cell-cell junctions: how to "open" the blood brain barrier.

Stamatovic SM, Keep RF, Andjelkovic AV. · 2008

Read Brain endothelial cell-cell junctions: how to "open" the blood brain barrier. by Stamatovic SM, Keep RF, Andjelkovic AV. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2687937.txt.

Introduction

Stamatovic, Keep, and Andjelkovic reviewed in 2008 how the blood-brain barrier, the sealed lining of brain blood vessels, gets pried open in disease. The barrier's tightness comes from junction complexes that glue neighboring lining cells together, blocking leaks between cells. Almost no traffic crosses by bubbles through the cells either, so the brain stays chemically sheltered.

In many brain disorders this seal fails. Inflammation, Alzheimer disease, Parkinson disease, and epilepsy can all loosen the junctions. Blood cells then slip into brain tissue, and fluid follows, swelling the brain. At the same time, the cells' bubble transport wakes up and ferries large molecules across. The review maps the routes of opening and the signal pathways that control them. Knowing the locks, the authors argue, is the start of learning to close the barrier again, or to open it briefly for drugs.

Catalog record

CREATORStamatovic SM, Keep RF, Andjelkovic AV.
YEAR2008
COLLECTIONPAPERS
FORMATTXT
FILE SIZE88 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2687937

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Brain Endothelial Cell-Cell Junctions: How to “Open” the Blood Brain Barrier By Svetlana M Stamatovic, Richard F Keep, Anuska V Andjelkovic Published in: Current Neuropharmacology DOI: 10.2174/157015908785777210 ABSTRACT Abstract The blood-brain barrier (BBB) is a highly specialized structural and biochemical barrier that regulates the entry of blood-borne molecules into brain, and preserves ionic homeostasis within the brain microenvironment. BBB properties are primarily determined by junctional complexes between the cerebral endothelial cells. These complexes are comprised of tight and adherens junctions. Such restrictive angioarchitecture at the BBB reduces paracellular diffusion, while minimal vesicle transport activity in brain endothelial cells limits transcellular transport. Under normal conditions, this largely prevents the extravasation of large and small solutes (unless specific transporters are present) and prevents migration of any type of blood-borne cell. However, this is changed in many pathological conditions. There, BBB disruption (“opening”) can lead to increased paracellular permeability, allowing entry of leukocytes into brain tissue, but also contributing to edema formation. In parallel, there are changes in the endothelial pinocytotic vesicular system resulting in the uptake and transfer of fluid and macromolecules into brain parenchyma. This review highlights the route and possible factors involved in BBB disruption in a variety of neuropathological disorders (e.g. CNS inflammation, Alzheimer’s disease, Parkinson’s disease, epilepsy). It also summarizes proposed signal transduction pathways that may be involved in BBB “opening”. INTRODUCTION “Good fences make good neighbors.” The blood-brain barrier (BBB) is a highly specialized structural, transport and biochemical (enzymatic) barrier, that mainly consists of microvascular endothelial cells and overlying astrocytic foot processes. It regulates the entry of compounds and cells between blood and brain and, thus, has a fundamental role in brain homeostasis. It also, though, forms a route of communication between circulating blood and underlying brain tissues [125,142,173]. Much of the structural barrier is due to the presence of tight junctions between the cerebral endothelial cells that limit paracellular diffusion. Those junctions, how they are regulated, how they are affected by disease states and how they can be manipulated therapeutically is the main focus of this review. Other reviews discuss other BBB properties (e.g. transport and enzymatic barrier properties) in depth. BBB STRUCTURE: THE JUNCTIONAL COMPLEXES BBB properties are primarily determined by endothelial junctional complexes consisting of tight junctions (TJ) and adherens junctions (AJ). It is generally accepted that TJ seal the interendothelial cleft forming a continuous blood vessel, while the AJ are important for initiating and maintaining endothelial cell-cell contact [60,142]. The tight junctions between BBB endothelial cells lead to high endothelial electrical resistance and low paracellular permeability. The electrical resistance is in the range of 1500-2000 Ω.cm2 (pial vessels) compared to 3-33 Ω.cm2 in other tissues [27,40]. TJ and AJ are composed of transmembrane proteins and cytoplasmic plaque proteins (Fig. 1, Table 1). The former proteins physically associate with their counterparts on the plasma membrane of adjacent cells, whereas the latter provide a link between transmembrane TJ/AJ proteins and the actin cytoskeleton but also participate in intracellular signaling [60,142]. [Figure: Structural features of the brain endothelial junctional complex.] [Table: Proteins Identified in Brain Endothelial Junctional Complex] Transmembrane proteins of the TJ include occludin, claudins (for example, claudin-3, -5, -12) and junctional adhesion molecule (JAM)-A, JAM-B and JAM-C [32,60,103]. Occludin was one of the first TJ transmembrane proteins described. Structurally, occludin contains two equal extracellular loops (44 amino acids), four transmembrane domains and three cytoplasmic domains: one intracellular short turn, a small N-terminal domain and a long carboxyl (C-) terminal [60,92,119,150]. It is thought that both of the extracellular loops provide the gate and fence-like structure of TJs, although the function of first extracellular loop is mostly involved in intercellular adhesion, while second loop mostly affects transendothelial electrical resistance [50,119]. The C-terminal domain (150 amino acids) of occludin is remarkably conserved between species and it is predicted to form a typical α-helical coiled-coil structure [92,119]. Through this structure occludin can associate with ZO-1, ZO-2 and ZO-3, directly bind to F-actin, and interact with regulatory protein PKCζ, tyrosine kinase c-Yes, PI3K and gap junction component connexin 26 [4,35,85,129,165,168]. As well as being involved in the integration and function of occludin in the TJ complex, this part of the molecule plays a critical role in paracellular channel formation and in mediating the endocytosis and trafficking of occludin [73,112,168]. The N-terminal site is critical for occludin function as an adhesion molecule and a N-terminal occludin mutant may be unable to fully oligomerize and completely assemble in TJ complexes [148]. Claudins are principal barrier-forming proteins that belong to the PMP22/EMP/MP20/claudin family of proteins [for review see 14, 36, 60, 70]. Until now, twenty different claudins have been identified and each of them shows a unique pattern of tissue expression. All claudins have the same structural pattern: four membrane-spanning regions, two extracellular loops and two cytoplasmic termini: a very short internal N-terminal sequence (2-6 amino acids) and a longer internal C-terminal sequence (21-63 amino acids) [36,70]. The first extracellular loop (49-52 amino acids) influences paracellular charge selectivity, while the second extracellular loop (16-33 amino acids) is the receptor for a bacterial toxin [56,60,80,143]. The C-terminus possesses the binding site for the cytoplasmic proteins ZO-1, ZO-2, ZO-3, MUPP1, PATJ through a PDZ motif [56,64,143]. Claudins function in the TJ complex is to limit paracellular ion movement selectively and this produces the high electrical resistance of the barrier [104,178]. Brain endothelial cells possess the claudin-5 and claudin-12 and possibly some other claudins [112,160]. Claudins present in brain endothelial cells may form pores of variable size (~10Å) which may be involved in transjunctional movement of water [17,104, 121,178]. Claudin-5 deletion did not inhibit tight junction formation but did result in a size-selective increase in permeability [70,110]. JAMs (JAM-A, -B, -C) are members of the immunoglobulin superfamily [15,16]. These molecules structurally are composed of a single membrane spanning domain, an extracellular domain, an extracellular N-terminus, and a short cytoplasmic C-terminus [15,16,159,186]. The extracellular region of JAMs consists of two IgG-like domains. These are often subclassified as C1-, C2-, V- and I-type based on the variable and constant regions of antibodies [15,159,186]. The extracellular domain appears to be subject of glycosylation, although the function of this is still unknown [186]. The N-terminal loop can be dimerized. The short C-terminus cytoplasmic tail (40 amino acids) contains a PDZ binding domain which facilitates interactions with TJ associated scaffold proteins such as ZO-1, AF-6, ASIP/Par3, and cingulin [74,124]. The cytoplasmic tail also contains consensus phosphorylation sites that may serve as substrates for PKC and PKA [36,123,165]. New evidence also suggests that this cytoplasmic tail may be involved in targeting JAM to intercellular junctions. In general, JAMs are expressed at the intracellular junctions of endothelial and epithelial cells and display different patterns of homo- and heterophilic adhesion [15,86,144]. Homophilic interactions are with molecules on the opposite cell, forming JAM dimers that are part of tight junction structure [15,144]. Heterophilic interactions, however, can occur between different JAM family members as well as other adhesion molecules (e.g. integrins) and their function is still unknown [86]. Regarding the function JAMs at the level of the TJ complex, these molecules are involved in promoting the localization of ZO-1, AF6, CASK and occludin at points of cell contact and, via targeting Par3, are involved

Read the complete text